Modeling the cGAS-STING signaling pathway in distinct environments (infected or inflamed tissues, tumor, immune-privileged organs,...) and pathophysiological contexts (chronic inflammation, immunosuppression, ...) constitutes an important challenge to improve the prediction of disease outcomes and reduce the high failure rates of clinical trials. This evidence concerns the gene STING1 and neoplasm.